Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice

Availability of novel hormonal therapies as well as docetaxel and cabazitaxel treatment for metastatic castration-resistant prostate cancer (CRPC) has changed the outlook for this group of patients with improvements in progression-free survival and overall survival. Physicians often diagnose the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizokami, Atsushi, Izumi, Kouji, Konaka, Hiroyuki, Kitagawa, Yasuhide, Kadono, Yoshifumi, Narimoto, Kazutaka, Nohara, Takahiro, Bahl, Amit K, Namiki, Mikio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312209/
https://www.ncbi.nlm.nih.gov/pubmed/27270339
http://dx.doi.org/10.4103/1008-682X.179159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312209/
https://www.ncbi.nlm.nih.gov/pubmed/27270339
http://dx.doi.org/10.4103/1008-682X.179159

Ejemplares similares